Skip to content

Personalized Follow-up Program in the Type 2 Diabetes Prevention

Personalized Follow-up Program in the Type 2 Diabetes Prevention

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04907760
Acronym
PROXIPART
Enrollment
230
Registered
2021-06-01
Start date
2021-10-10
Completion date
2026-10-10
Last updated
2021-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes

Keywords

Diabetes, Metabolic Diseases, Endocrine System Diseases, Prevention

Brief summary

In France, the global prevalence of diabetes was estimated to 5% of the population in 2016, the type two diabetes (DT2) corresponding to 90% of cases. This number is widely underestimated because most people are untreated and undiagnosed. Due to the silent character of this disease, it is estimated that 20 à 30 % of diabetic adults have not yet been diagnosed. The conclusions, presented during the annual meeting of EASD in 2019, suggest that the precursor signs of this disease could be present until 20 years before the diagnosis. Diabetes is a metabolic disease and people are diagnosed, in general, around 40-50 years old. The main risk factor of type II diabetes is lifestyle (rich diet, sedentary) but there is also other factors like hyperlipidemia, high blood pressure, high fasting blood sugar, stress, smoking, heredity, family history of diabetes, or gestational diabetes. This induces an increase of obesity, itself a major risk factor for type II diabetes occurrence. From an economical aspect, chronic pathologies (including diabetes) represent 60% of health insurance expenses, even though it concerns 35% of insured persons, i.e. 20 million of patients. The average of annual reimbursement for a type 2 diabetic patient is 4890 euros. In this context, this study is the first step of thinking about a different, coordinated care approach, based on a preventive rather than curative approach.

Detailed description

This study includes a personalized care program, including the patient follow-up by a nurse during 5 years with a contact every 4 months for the first year, then after every 6 months. The nurse will review the patient's progress and provide advice and contact with professionals: physical activity, psychologists, dieticians, endocrinologists, etc The main objective of this study is to compare, after 5 years of follow-up, the risk factors associated with type 2 diabetes, between participants who received personalized follow-up and those who did not. The secondary objectives are to compare the occurrence of type 2 diabetes, the quality of life and the compliance to the program between participants who received personalized follow-up and those who did not.

Interventions

OTHERPersonalized care program

It includes the participant follow-up by a nurse during 5 years with a contact every 4 months for the first year, then after every 6 months

Sponsors

GCS Ramsay Santé pour l'Enseignement et la Recherche
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Interventional, prospective, randomized, controlled, two arms, multicentric study

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Person with a FINDRISC score ≥ 10 points * Person who has given his/her express written and informed consent

Exclusion criteria

\- Person already diagnosed with a type 2 diabetes

Design outcomes

Primary

MeasureTime frameDescription
Risk factors for type 2 diabetes in participants5 yearsFinnish Diabetes Risk Score (FINDRISC score) : 8 items with a total score from 0 to 26 points with 0 (no risk factor) and 26 (highest risk factor)

Secondary

MeasureTime frameDescription
Diabetes diagnosticat 5 yearsmeasuring fasting blood glucose
The Quality of Lifeat 5 yearsWHO questionary : total score out of 100, 26 questions with 5 likert scale items
program complianceduring 5 yearsCompliance is based on all the scheduled visits, the number of visits not carried out and the time during the research will be described in each group.

Contacts

Primary ContactAurelie LIETAER, MD
a.lietaer@yahoo.fr33 (0)5 59 57 75 60

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026